Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease : An Overview of Switching Between Pharmacological Agents
Blesa, Rafael (Institut d'Investigació Biomèdica Sant Pau)
Toriyama, Kazuhiro (Novartis Pharma KK, Tokyo)
Ueda, Kengo (Novartis Pharma KK, Tokyo)
Knox, Sean (Novartis Pharma AG, Basel)
Grossberg, George (Saint Louis University School of Medicine)
Universitat Autònoma de Barcelona

Data:	2018
Resum:	Alzheimer's disease (AD) is the most common cause of dementia, characterized by a progressive decline in cognition and function. Current treatment options for AD include the cholines-terase inhibitors (ChEIs) donepezil, galantamine, and rivastigmine, as well as the N-methyl-D-aspartate receptor antagonist memantine. Treatment guidelines recommend the use of ChEIs as the standard of care first-line therapy. Several randomized clinical studies have demonstrated the benefits of ChEIs on cogni-tion, global function, behavior and activities of daily living. However, patients may fail to achieve sus-tained clinical benefits from ChEIs due to lack/loss of efficacy and/or safety, tolerability issues, and poor adherence to the treatment. The purpose of this review is to explore the strategies for continued successful treatment in patients with AD. Literature search was performed for articles published in PubMed and MEDLINE, using pre-specified search terms. Articles were critically evaluated for inclusion based on their titles, abstracts, and full text of the publication. The findings of this review indicate that dose up-titration and switching between ChEIs may help to improve response to ChEI treatment and also address issues such as lack/loss of effica-cy or safety/tolerability in patients with AD. However, well-designed studies are needed to provide robust evidence.
Nota:	Altres ajuts: This review article is sponsored by Novartis Pharma K.K., Tokyo, Japan. The publication processing fees were funded by Novartis Pharma K.K., Tokyo, Japan.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Alzheimer's disease ; Switching ; AD treatment ; Cholinesterase inhibitors ; Dementia ; Adherence
Publicat a:	Current Alzheimer Research, Vol. 15 (october 2018) , p. 964-974, ISSN 1875-5828

DOI: 10.2174/1567205015666180613112040
PMID: 29895249

11 p, 797.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats